Search

Your search keyword '"Hans Wildiers"' showing total 590 results

Search Constraints

Start Over You searched for: Author "Hans Wildiers" Remove constraint Author: "Hans Wildiers"
590 results on '"Hans Wildiers"'

Search Results

1. Reporting on patient’s body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review

2. Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program

3. Reporting on invasive lobular breast cancer in clinical trials: a systematic review

4. Metastases of primary mixed no-special type and lobular breast cancer display an exclusive lobular histology

5. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer‐specific survival

6. A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry

7. Obesity-associated changes in molecular biology of primary breast cancer

8. Trial watch: chemotherapy-induced immunogenic cell death in oncology

9. Diagnostic Performance of Screening Tools for Depressive Symptoms in Vulnerable Older Patients with Cancer Undergoing Comprehensive Geriatric Assessment (CGA): Results from the SCREEN Pilot Study

10. Correlation of TROP-2 expression with clinical–pathological characteristics and outcome in triple-negative breast cancer

11. Incidence of falls and fall-related injuries and their predictive factors in frail older persons with cancer: a multicenter study

12. Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study

13. Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast

14. Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression

15. Mortality and Major Adverse Cardiac Events in Patients With Breast Cancer Receiving Radiotherapy: The First Decade

16. Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology

17. Impact of baseline telomere length on survival and chemotherapy related toxicity in breast cancer patients receiving (neo)adjuvant anthracycline containing chemotherapy

18. Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer

19. Dynamic alterations of immunosenescence-related genes in older women with breast cancer receiving chemotherapy: A prospective study

20. Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk

21. Cause of death for patients with breast cancer: discordance between death certificates and medical files, and impact on survival estimates

22. The Combination of the CDK4/6 Inhibitor, Palbociclib, With the Vitamin D3 Analog, Inecalcitol, Has Potent In Vitro and In Vivo Anticancer Effects in Hormone-Sensitive Breast Cancer, But Has a More Limited Effect in Triple-Negative Breast Cancer

23. The added value of supervised hydrotherapy sessions to a 12-week exercise program after breast cancer treatment: a three-arm pseudo-randomized pilot study

24. Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells

25. A mindfulness-based intervention for breast cancer patients with cognitive impairment after chemotherapy: study protocol of a three-group randomized controlled trial

26. Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris

27. Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline / mutations and hormone receptor status from the phase-3 BROCADE3 trial

28. 948 Final results from AIPAC: A phase IIb comparing eftilagimod alpha (a soluble LAG-3 protein) vs. placebo in combination with weekly paclitaxel in HR+ HER2- MBC

29. Is cancer biology different in older patients?

30. Initiation and termination of dialysis in older patients with advanced cancer: providing guidance in a complicated situation

31. Anticancer drugs are not well tolerated in all older patients with cancer

32. Oncological care organisation during COVID-19 outbreak

33. Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis

34. Age‐related remodelling of the blood immunological portrait and the local tumor immune response in patients with luminal breast cancer

35. Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy

36. Oncological safety of autologous breast reconstruction after mastectomy for invasive breast cancer

37. A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

38. Systematic development of CHEMO-SUPPORT, a nursing intervention to support adult patients with cancer in dealing with chemotherapy-related symptoms at home

39. POLRMT as a Novel Susceptibility Gene for Cardiotoxicity in Epirubicin Treatment of Breast Cancer Patients

40. Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study

41. The utilization of formal and informal home care by older patients with cancer: a Belgian cohort study with two control groups

42. The footprint of the ageing stroma in older patients with breast cancer

43. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus

44. Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer

45. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016

46. Circulating MicroRNAs as easy-to-measure aging biomarkers in older breast cancer patients: correlation with chronological age but not with fitness/frailty status.

47. Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC).

48. Proteolytic processing of ErbB4 in breast cancer.

49. Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC).

Catalog

Books, media, physical & digital resources